Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

Leukemia

Volumn 23, Issue 7, 2009, Pages 1297-1302

  Garg, R ^a   Faderl, S ^a   Garcia Manero, G ^a   Cortes, J ^a   Koller, C ^a   Huang, X ^a   York, S ^a   Pierce, S ^a   Brandt, M ^a   Beran, M ^a   Borthakur, G ^a   Kantarjian, H ^a   Ravandi, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR15 ANTIGEN; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; APLASTIC ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOIDY; DRUG EFFICACY; DRUG FEVER; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FAILURE; LEUKOCYTOSIS; LEUKOPENIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

EID: 67650921718     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.28     Document Type: Article

References (27)

1. Young NS. Acquired aplastic anemia. Ann Intern Med 2002; 136 534-546.
2. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365-1372.
3. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15-29.
4. Gordon-Smith EC, Marsh JC, Gibson FM. Views on the pathophysiology of aplastic anemia. Int J Hematol 2002; 76 (Suppl 2): 163-166.
5. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anemia: Molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004; 364: 355-364.
6. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101: 1236-1242.
7. Marsh J. Making therapeutic decisions in adults with aplastic anemia. Hematology (Am Soc Hematol Educ Program) 2006; 1: 78-85.
8. Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131: 401-408.
9. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A et al. Antilymphocyte globulin, cyclosporine, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood 1995; 85: 1348-1353.
10. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85: 3058-3065.
11. Tichelli A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Wodnar-Filipowicz A et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anemia. Br J Haematol 1998; 100: 393-400.
12. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000; 72 131-133.
13. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003; 120: 679-684.
14. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al Cytogenetic analysis has strong predictive value in de novo MDS and can be incorporated in a new scoring system. Leukemia 1993; 7: 1315-1319.
15. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit antithymocyte globulin and cyclosporine for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006; 133: 622-627.
16. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387-1394.
17. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndrome. Blood 2000; 96 3671-3674.
18. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995; 14: 357-379.
19. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 1996; 14: 296-303.
20. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998; 17: 1563-1580.
21. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP et al. HLA-DR15 (DR2) is overrepresented in MDS and aplastic anemia and predicts a response to immunosuppression in MDS. Blood 2002; 100: 1570-1574.
22. Locasciulli A, Bruno B, Rambaldi A, Saracco P, Dufour C, Finelli C et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine, and two difference granulocyte colony-stimulating factor regimens: A GITMO prospective randomized study. Haematologica 2004; 89: 1054-1061.
23. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: Anti-thymocyte globulin, cyclosporine and mycophenolate mofetil. Br J Haematol 2006; 133 606-611.
24. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999; 107: 330-334.
25. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Inter Med 2002; 137: 156-163.
26. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK et al A prospective, randomized, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460-465.
27. Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndrome. Haematologica 2006; 91: 667-670.